Monitoring adverse events of vaccines against Mexican flu

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 2, 2011, Pages 81-87

  Van Puijenbroek, E P ^a   Van Grootheest, A C ^a  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

Author keywords

H1N1; new influenza A (H1N1); side effects; Swine flu

Indexed keywords

INFLUENZA VACCINE;

ANAPHYLACTIC SHOCK; ANAPHYLAXIS; ARTICLE; BELL PALSY; CARDIOVASCULAR DISEASE; CONVULSION; COUGHING; CYSTIC FIBROSIS; DEMYELINATING DISEASE; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FATIGUE; FETUS DEATH; FEVER; GASTROINTESTINAL HEMORRHAGE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; KIDNEY DISEASE; LOCAL SKIN REACTION; LUNG DISEASE; MEXICAN FLU; MEXICAN INFLUENZA; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NETHERLANDS; NEURITIS; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; RASH; REGISTRATION; SIDE EFFECT; SPONTANEOUS ABORTION; SWINE INFLUENZA; VASCULITIS; VOMITING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG MONITORING; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINATION;

EID: 80052053188     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0525     Document Type: Article

References (10)

1. Statement from WHO Global Advisory Committee on Vaccine Safety about the safety profile of pandemic influenza A (H1N1) 2009 vaccines.WHO;18 december 2009.Available from: Http://www.who.int/csr/resources/publications/swineflu/ gacvs-statement-20091218/en/index.html
2. Productinformation pandemic influenzavaccin (Focetria®). Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000710/WC500023756.pdf.
3. Gezondheidsraad. Vaccinatie tegen pandemische influenza A/H1N1 2009: Doelgroepen en prioritering, (Vaccination against pandemic Influenza A/H1N1 2009: Target groups and prioritizing).Available from: Http://www. gezondheidsraad.nl/ sites/default/files/200910-0.pdf.
4. Product information pandemic influenzavaccin (Pandemrix®). Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000832/WC500038122.pdf
5. Minister van VWS, Brief aan de Voorzitter van de Tweede Kamer, 5maart 2010, (Ministry of Health,Welfare and Sports - letter to the chairman of the House of Representatives of the Netherlands). Available from: Http://www.rijksoverheid.nl/ documenten-en-publicaties/kamerstukken/2010/03/05/ nieuwe-influenza-a-h1n1.html
6. A.C. van Grootheest and N. Broos, Veilig vaccineren. Bijwerkingen melden vergroot vertrouwen in vaccinatiecampagne, (Safe vaccination. Reporting ADRs increases the conficende in the vaccination campaign), Med Contact 64 (2009), 1757-1760.
7. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine Revision 1.0. European Medicines Evaluation Agency. Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/ Report/2010/01/WC500051739.pdf.
8. E.P. van Puijenbroek, N. Broos and A.C. vanGrootheest, Monitoring adverse events of the vaccination campaign against Influenza A (H1N1) in the Netherlands, Drug Saf 33(12) (2010), 1097-1108.
9. Eurosurveillance editorial team. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe [document op het internet]. Eurosurveillance; 1 October 2009. Available from: Http://www.eurosurveillance.org/images/dynamic/EE/V14N39/art19345.pdf.
10. N. Broos, E.P. van Puijenbroek and A.C. van Grootheest, Fever following immunization with Influenza A/H1N1 vaccine in children: A survey-based study in the Netherlands, Drug Saf 33(12) (2010), 1109-1115.